We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Synthetic Thymus Hormone Increases Therapeutic Power of Brain Cancer Drugs

By LabMedica International staff writers
Posted on 01 Feb 2010
A synthetic hormone, based on one produced by the thymus gland, has been shown to boost the effects of chemotherapeutic agents used to treat glioblastoma, an aggressive and deadly form of brain cancer.

Investigators at Brown University (Providence, RI, USA) worked with a synthetic form of thymosin alpha 1 (Talpha1 or thymalfasin), which is an analogue of the hormone thymosin produced naturally by the thymus gland. More...
Since thymosin is being used in Europe to treat cancer, the American group decided to evaluate the potential of the synthetic analogue.

Talpha1 is an immunomodulator that increases interleukin-2 (IL-2) production and T-cell proliferation. In the current study, the investigators examined the potential therapeutic effects of Talpha1 in experimental in vivo glioblastoma, and characterized Talpha1's anti-tumor effects in vitro. In addition, Rar 9L cancer cells were implanted into the right frontal lobe of adult Long Evans rats. The rats were then treated with Talpha1 alone or in conjunction with the chemotherapeutic drug BNCU (Carmustine) or with only BNCU.

Results published in the December 2009 issue of the Journal of Oncology revealed that while Talpha1 had no direct effect on viability or mitochondrial function, it increased expression of proapoptosis genes, including FasL, FasR, and TNF-alpha-R1 (65.89%, 44.08%, and 22.18%, respectively), and increased 9L cell sensitivity to oxidative stress. Moreover, Talpha1 enhanced 9L cell sensitivity to both Granzyme B- and BCNU-mediated killing.

"We looked at giving chemo plus Talpha1 as a sort of immune booster," explained senior author Dr. Suzanne de la Monte, professor of neuroscience at Brown University. "What we found is that when you give Talpha1 and the chemo agent together, not only do you have a slower rate of tumor growth with cells being killed, but there have also been cures. We achieved a 25% cure rate in these animal models. Talpha1 sensitizes the tumor cells to the chemotherapeutic agent, giving the agent more of an impact upon the tumor than it would have on its own. The thymic hormone is actually working to boost immune response and basically activates a killing of the tumor cells."

The next step will be to evaluate the drug combination in a Phase I clinical trial. "You are talking about a disease where people are dead within months. There is no cure, said Dr. de la Monte."

Related Links:
Brown University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Immunofluorescence Analyzer
IFA System
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.